Table 2.
Long COVID Symptoms at Month 6 by COVID-19 Vaccination Status: observed and adjusted model-based results a.
| All (n = 444) |
BNT162b2 (n = 233) | Unvaccinated (n = 211) | Observed | Model-Based | |||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | p Value | OR (95% CI) | p Value | ||||
| Long COVID | |||||||
| ≥2 symptoms | 138 (31.1%) | 60 (25.8%) | 78 (37.0%) | 0.59 (0.39, 0.89) | 0.011 | 0.63 (0.41, 0.96) | 0.030 |
| ≥3 symptoms | 96 (21.6%) | 40 (17.2%) | 56 (26.5%) | 0.57 (0.36, 0.91) | 0.017 | 0.59 (0.36, 0.96) | 0.034 |
| Symptom category | |||||||
| General symptoms | 107 (24.0%) | 46 (19.6%) | 61 (28.9%) | 0.60 (0.39, 0.94) | 0.021 | 0.63 (0.40, 0.99) | 0.048 |
| Respiratory and cardio symptoms | 62 (13.9%) | 29 (12.3%) | 33 (15.6%) | 0.77 (0.45, 1.31) | 0.315 | 0.80 (0.47, 1.38) | 0.424 |
| Neurologic symptoms | 139 (31.2%) | 61 (26.0%) | 78 (37.0%) | 0.60 (0.40, 0.91) | 0.012 | 0.60 (0.39, 0.92) | 0.018 |
| Digestive/other symptoms | 82 (18.4%) | 36 (15.3%) | 46 (21.8%) | 0.66 (0.40, 1.06) | 0.078 | 0.69 (0.42, 1.13) | 0.137 |
a Based on mixed-effects logistic models with unstructured correlation matrix. Covariates were sociodemographic characteristics (age, sex, regions, social vulnerability, race/ethnicity), variables for time, vaccination status and interaction of time by vaccination status, as well as ≥1 comorbidity, previously tested positive for COVID-19, and Nirmatrelvir/Ritonavir prescription. OR = odds ratio; CI = confidence interval.